{"id":6372,"date":"2026-01-27T08:23:08","date_gmt":"2026-01-27T14:23:08","guid":{"rendered":"https:\/\/www.vanderbilt.edu\/csb\/?p=6372"},"modified":"2026-01-27T08:23:08","modified_gmt":"2026-01-27T14:23:08","slug":"csb-research-spotlight-georgiev-lab-developing-antibody-therapeutics-against-existing-and-emerging-viral-threats","status":"publish","type":"post","link":"https:\/\/www.vanderbilt.edu\/csb\/2026\/01\/27\/csb-research-spotlight-georgiev-lab-developing-antibody-therapeutics-against-existing-and-emerging-viral-threats\/","title":{"rendered":"CSB Research Spotlight: Georgiev Lab\u2014Developing antibody therapeutics against existing and emerging viral threats"},"content":{"rendered":"
The Georgiev lab recently led a multi-institutional study, published in the journal Cell, that focused on the development of antibody therapeutics against existing and emerging viral threats, including RSV (respiratory syncytial virus) and avian influenza viruses.<\/p>\n
The study showed that a protein language model could design functional human antibodies that recognized the unique antigen sequencies (surface proteins) of<\/p>\n
specific viruses, without requiring part of the antibody sequence as a starting template.<\/p>\n